The Limited Times

Now you can see non-English news...

Shock: Corona vaccine test stopped - subject suffers from "very serious syndrome"

2020-09-11T21:34:53.594Z


As one of nine pharmaceutical companies worldwide, AstraZeneca is in the crucial test phase for a corona vaccine. But the study has to be suspended.


As one of nine pharmaceutical companies worldwide, AstraZeneca is in the crucial test phase for a corona vaccine.

But the study has to be suspended.

  • AstraZeneca

    is considered to be a great hope in the development of a

    corona vaccine

    .

  • But now the British-Swedish pharmaceutical company has

    to stop the clinical test phase

    .

  • Here you will find the basic facts about the coronavirus * and the corona news from Germany.

    We also offer you the current number of cases in Germany on a map.

Update from September 10, 2020, 2:05 p.m.:

Research into a

vaccine

is considered one of the key factors to combat the

Sars-Cov-2 coronavirus

.

But now there was a major setback.

The British-Swedish pharmaceutical company

AstraZeneca

had to interrupt the third and therefore last phase of the clinical studies because

health problems occurred

in a

test person

.

Corona vaccine: study stopped - subject probably has "syndrome to be taken very seriously"

The group has so far remained covered with regard to the exact disease.

According to information from the

"New York Times"

(we reported, see first report), however, it is said to be

transverse myelitis

, an inflammation of the spinal cord.

In many cases this would recede completely, but "this is a syndrome to be taken very seriously", as the head of the Infectious Disease Department at Regensburg University Clinic, Professor

Bernd Salzberger

, told the "Bild" newspaper (article behind the payment barrier).

A time delay is now inevitable.

Dr.

Rolf Hömke

, research

sprecer of

the Association of Research-

Based

Pharmaceutical Companies, told the newspaper that the study "could be continued after a few days or weeks".

The spokesman for Health Minister

Jens Spahn

said that it was "the scientific standard" for a study to be stopped because of health problems of a participant.

Coronavirus: vaccine test stopped - test subject probably got sick with a rare disease

Our initial report from September 9, 2020:

Munich - All over the world people long for a

vaccine

to be able to fight the corona pandemic * effectively.

A company is well advanced in developing a serum.

The British-Swedish pharmaceutical company

AstraZeneca

is one of nine companies worldwide in the third and final phase of clinical studies and is considered a great hope.

Tests with tens of thousands of participants were running.

Corona vaccine: AstraZeneca has to interrupt the test phase

But in the race to get a vaccine * approved,

AstraZeneca has

now suffered a major setback.

The clinical was stopped for the time being

because one of the subjects had health problems

.

This is a routine measure "that must be carried out whenever a potentially inexplicable disease occurs in one of the studies," said a company spokesman.

He went on to say that the process had been voluntarily interrupted "in order to allow the safety data to be checked by an independent committee." It was necessary to clarify whether the health problems of the study participant were due to side effects of the active ingredient AZD1222.

Tests for corona vaccine interrupted: patient is said to have rare neurological disease

AstraZeneca

did not provide any information

about the disease or where the patient is

.

But there are conjectures and rumors.

The

New York Times claims

to have learned from an informed person that the patient is said to have transverse myelitis.

This is a rare neurological disorder caused by inflammation of the central nervous system caused by viruses.

Breaking News: A major coronavirus vaccine trial was halted because of a serious adverse reaction in a participant, the pharmaceutical company AstraZeneca said.

https://t.co/PC4EYqPr1c

- The New York Times (@nytimes) September 8, 2020

The

active ingredient AZD1222 manufactured

by

AstraZeneca

is based on the weakened version of a cold virus from chimpanzees and is supposed to get the immune system going so that it can fight Sars-CoV-2 * in the event of infection.

(mt / dpa) * Merkur.de is part of the nationwide Ippen digital editorial network.

List of rubric lists: © Ted S. Warren / dpa

Source: merkur

All news articles on 2020-09-11

You may like

News/Politics 2024-03-18T14:18:09.201Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.